Dupixent®（杜炳單抗）在中國獲批，成爲慢性阻塞性肺疾病（COPD）患者首個生物製劑

快訊 · 09/27 19:00

Dupixent® (Dupilumab) Approved in China as the First-Ever Biologic Medicine for Patients With Chronic Obstructive Pulmonary Disease (Copd)

Dupixent®（杜炳單抗）在中國獲批，成爲慢性阻塞性肺疾病（COPD）患者首個生物製劑藥物。